Stay up-to-date with the latest developments in gene and cell therapy by subscribing to our newsletter.
Featured:
Jul 23 | Dispatch Bio Emerges from Stealth with $216M to Tackle Solid Tumors read more »
Jul 23 | Solid Biosciences’ AAV Gene Therapy SGT-501 Granted FDA Fast Track for CPVT read more »
Jul 22 | Precision BioSciences Receives FDA Orphan Drug Designation for Gene Therapy PBGENE-DMD read more »
News:
Jul 24 | Pierre Fabre Pharmaceuticals and Atara Biotherapeutics Advance Cell Therapy with FDA Priority Review read more »
Jul 24 | Genflow Biosciences Advances Key AAV Longevity Programs GF-1002 and GF-1004 read more »
Jul 23 | Opus Genetics Partners with Global RDH12 Alliance to Accelerate Gene Therapy for IRDs read more »
Jul 22 | CBO Report: NIH Cuts and FDA Delays Could Significantly Reduce New Drug Development read more »
Jul 22 | Sarepta Pauses DMD Gene Therapy Shipments Following FDA Request read more »
Jul 22 | Orbital Therapeutics Unveils Preclinical Data for In Vivo Circular RNA CAR-T in Autoimmune Disease read more »
Jul 21 | Recent Publication Highlights Gene Editing Breakthrough for Alternating Hemiplegia of Childhood (AHC) read more »
Articles:
Jul 23 | Recreating pathophysiology of CLN2 disease and demonstrating reversion by TPP1 gene therapy in hiPSC-derived retinal organoids and retina-on-chip read more »
Jul 23 | Gene therapy ameliorates neuromuscular pathology in CLN3 disease read more »
Jul 22 | Efficient in vivo targeting of the myocardial scar using Moloney murine leukaemia virus complexed with nanoparticles read more »
Jul 21 | In vivo prime editing rescues alternating hemiplegia of childhood in mice read more »
Jul 19 | High-throughput evaluation of cardiac-specific promoters for adeno-associated virus mediated cardiac gene therapy read more »
Jul 18 | Long-Term Functional Correction of Pompe Disease and Increased α-Glucosidase Expression after Gene Therapy with Novel Combinations of Muscle-Targeted Transcriptional Cis-Regulatory Elements read more »
Jul 17 | Therapeutic AASS inhibition by AAV-miRNA rescues glutaric aciduria type I severe phenotype in mice read more »
Jul 17 | AAV-delivered PPT1 provides long-term neurological benefits in CLN1 mice and achieves therapeutic levels in sheep brain read more »
Jul 16 | Efficient in vivo generation of CAR T cells using a retargeted 4th generation lentiviral vector read more »
Jul 16 | Noncanonical and mortality-defining toxicities of CAR T cell therapy read more »
Jul 16 | Directed evolution expands CRISPR–Cas12a genome-editing capacity read more »
Jul 16 | IL-12 mRNA-LNP promotes dermal resident memory CD4+ T cell development read more »
Jul 01 | Viral and non-viral vectors in gene therapy: current state and clinical perspectives read more »
About PackGene
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
